Efficacy of Pentoxifylline on Cerebrovascular Function in Patients With Cerebral Small Vessel Disease(PERFORM)
NCT05583266, Phase 4, Unknown, Beijing Tiantan Hospital
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Efficacy of Pentoxifylline on Cerebrovascular Function in Patients With Cerebral Small Vessel Disease(PERFORM) | ClinicalTrials.gov |
| NCT number | NCT05583266 | ClinicalTrials.gov |
| Status | Unknown | ClinicalTrials.gov |
| Phases | Phase 4 | ClinicalTrials.gov |
| Enrollment | 80 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Beijing Tiantan Hospital | ClinicalTrials.gov |
| Conditions | Cerebral Small Vessel Diseases | ClinicalTrials.gov |
| Interventions | Pentoxifylline sustained-release tablets, Pentoxifylline sustained-release tablets placebo | ClinicalTrials.gov |
| First posted | 2022-10-17 | ClinicalTrials.gov |
| Last updated | 2022-10-17 | ClinicalTrials.gov |
Registered outcomes 16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | The change in cerebral blood flow at 6 months | 3 months and 6 months after randomization | TCD is used to evaluate the change in cerebral blood flow (cm/s) 6 months after treatment. Higher speed mean a worse outcome. | ClinicalTrials.gov |
| Primary | The change of middle cerebral artery pulsatility index at 6 months | 3 months and 6 months after randomization | TCD is used to evaluate the change of middle cerebral artery pulsatility index at 6 months. Higher pulsatility index mean a worse outcome. | ClinicalTrials.gov |
| Secondary | cognitive function assessed by MoCA at 6 months | 6 months after randomization | Cognition function assessed by Montreal Cognitive Assessment (MoCA) score. Score range 0-30. Higher scores mean a better outcome. | ClinicalTrials.gov |
| Secondary | cognitive function assessed by Clinical Dementia Rating (CDR) at 6 months | 6 months after randomization | Cognitive function assessed by Clinical Dementia Rating (CDR). Score range 0-3. Higher scores mean a worse outcome. | ClinicalTrials.gov |
| Secondary | The change of White Matter hyperintense volume at 6 months | 6 months after randomization | WMH volume is assessed on 3D fluid attenuated inversion recovery (FLAIR) sequence in mm3 or cm3. Larger volume indicates a worse outcome. | ClinicalTrials.gov |
| Secondary | The change of White Matter hyperintensities Fazekas scores at 6 months | 6 months after randomization | Fazekas score is used to describe the different types of hyperintense signal abnormalities surrounding the ventricles and in the deep white matter. Periventricular hyperintensity (PVH) is graded as 0 = absence, 1 = "caps" or pencil-thin lining, 2 = smooth "halo", 3 = irregular PVH extending into the deep white matter. Separate deep white matter hyperintensity (DWMH) is rated as 0 = absence, 1 = punctate foci, 2 = beginning confluence of foci, 3 = large confluent areas. Higher scores indicats a worse outcome. | ClinicalTrials.gov |
| Secondary | The change of Cerebral blood flow values for MRI cerebral perfusion imaging at 6 months | 6 months after randomization | MRI is used to evaluate the change of Cerebral blood flow values for MRI cerebral perfusion imaging at 6 months. | ClinicalTrials.gov |
| Secondary | Digit span test | 6 months after randomization | The Digit span test is used to assess cognitive function change for 6 months. The score ranges from 0 to 44. Higher scores mean a better outcome. | ClinicalTrials.gov |
| Secondary | Stroop Color Word Test | 6 months after randomization | The Stroop Color and Word Test is a neuropsychological test extensively used to assess the ability to inhibit cognitive interference that occurs when the processing of a specific stimulus feature impedes the simultaneous processing of a second stimulus attribute, well-known as the Stroop Effect. Shorter the test time, the better the outcome. | ClinicalTrials.gov |
| Secondary | Hamilton Anxiety Scale(HAMA) | 6 months after randomization | Mood function is assessed by Hamilton Anxiety Scale(HAMA). The Score ranges 0-56. Higher scores mean a worse outcome. | ClinicalTrials.gov |
| Secondary | Hamilton Depression Scale(HAMD) | 6 months after randomization | Mood function assessed by Hamilton Depression Scale(HAMD). The Score ranges 0-68. Higher scores mean a worse outcome. | ClinicalTrials.gov |
| Secondary | The Short Physical Performance Battery(SPPB) | 6 months after randomization | It is a composite measure assessing walking speed, standing balance, and sit-to-stand performance. It has primarily been used to assess elderly patients both in the hospital and community setting. | ClinicalTrials.gov |
| Secondary | Urination and defecation | 6 months after randomization | The score of the urination and defecation function scale changed at 6 months. | ClinicalTrials.gov |
| Other | Neurovascular coupling index | 3 months and 6 months after randomization | Data are presented as peak population normalized mean changes from baseline, and median area under the curve (AUC). | ClinicalTrials.gov |
| Other | Electroencephalogram oscillations | 3 months and 6 months after randomization | The amplitude, frequency, phase, coherence will be measured. | ClinicalTrials.gov |
| Other | Blood-Brain Barrier (BBB) Permeability between groups. | 3 months and 6 months after randomization | BBB permeability is assessed by MRI and biomarker (including NSE, GFAP, S100β). | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 2
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Digit Span Test | Secondary outcome | ConductCognition |
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)